SCHEMBL696362

SCHEMBL696362

Cc1ccccc1-n1cc[c]n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.40
FLT3 P36888 1/20 0.39
GSK3B P49841 1/20 0.39
ADRB1 P08588 1/20 0.39
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
ADORA3 P0DMS8 2/20 0.38
MEN1 O00255 1/20 0.38
ADORA2A P29274 1/20 0.38
ALDH1A1 P00352 4/20 0.37
MGLL Q99685 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
HTT P42858 1/20 0.35
RXRA P19793 2/20 0.35
GRIN1 Q05586 2/20 0.35
GRIN2B Q13224 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2751397 0.85 ADRB1 (0.42) TSHRADRB1KMT2AMAPTMEN1
SCHEMBL2751180 0.78 ALDH1A1 (0.34) TSHRKMT2AMEN1ALDH1A1HCAR1
SCHEMBL2750740 0.78 NPSR1 (0.43) KMT2AMAPTALDH1A1SMN1; SMN2TDP1
SCHEMBL7220695 0.77 MAPK14 (0.38) KMT2AALDH1A1LMNAHCAR1
SCHEMBL69609 0.71 NOTUM (0.39) TSHRMAPTADORA3ADORA2AHPGD
SCHEMBL1969402 0.70 NOTUM (0.43) ADRB1HCAR1
SCHEMBL2751482 0.70 RXRA (0.38) RXRAGRIN1GRIN2BHCAR1
SCHEMBL17797064 0.69 APLNR (0.36) L3MBTL1
SCHEMBL29417843 0.68 MAPK1 (0.56) TSHRFLT3GSK3BKMT2AMAPT
SCHEMBL2454736 0.68 MAPK1 (0.56) TSHRFLT3GSK3BKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US claimed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP claimed
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US claimed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
EP-2061449-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES Leo Pharma A/S (DK) 2009-05-27 EP claimed
WO-2008019690-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2008-02-21 WO claimed
CN-114452912-B Preparation method of polysubstituted nitrogen-containing heterocyclic methylamine compound 上海罕道医药科技有限公司 2023-09-12 CN disclosed
CN-114452912-A Preparation method of polysubstituted nitrogen-containing heterocyclic methylamine compound 上海罕道医药科技有限公司 2022-05-10 CN disclosed
EP-3555098-A1 MESOIONIC IMIDAZOPYRIDINES FOR USE AS INSECTICIDES Bayer Aktiengesellschaft (DE) 2019-10-23 EP disclosed
WO-2018108730-A1 MESOIONIC IMIDAZOPYRIDINES FOR USE AS INSECTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2018-06-21 WO disclosed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed
EP-2061449-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES Leo Pharma A/S (DK) 2009-05-27 EP disclosed
WO-2008019690-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2008-02-21 WO disclosed
US-6605631-B1 Controlling fungi and pests; improved activity and plant tolerability BASF AKTIENGESELLSCHAFT (DE) 2003-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES C1R, C3AR1, PTH1R TSHR 61/4885FLT3 3549/4885GSK3B 3670/4885
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 TSHR 2043/4885FLT3 1938/4885GSK3B 4000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.